Novo Nordisk’s shares fell 6% on the news.
Ozempic does not slow Alzheimer’s progression, its manufacturer Novo Nordisk said following a two-year study.
The popular drug reduces body weight by on average around 15% in obese patients, and early data suggested it may also slow the progress of s... [257 chars]